264P Split-dose intravenous delivery of igrelimogene litadenorepvec enhances viral levels in blood and tumours compared with conventional intratumoral injection

Oncolytic virotherapy has the potential to expand the therapeutic application of immunotherapy. Because of its replicative nature, route and frequency of administration, critically impact clinical outcomes and real-world applicability. A schism within the field centers on whether systemic or local administration offers the most effective approach for delivering oncolytic virotherapy.